Pharmaceutical sponsor
MediLink Therapeutics (Suzhou) Co., Ltd. Clinical Trials
Studies where MediLink Therapeutics (Suzhou) Co., Ltd. is the lead sponsor: its pipeline by phase, what is enrolling now and where. Studies it supports as a collaborator are in the search.
In numbers
Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.
Open to volunteers
All 18Non Small Cell Lung Cancer, Colorectal Cancer
A Study of YL202 in Patients With Advanced Solid Tumors
This study is a multicenter, open-label, phase II study of YL202 in China to evaluate the efficacy, safety, and PK characteristics of YL202 in selected patients with advanced solid tumors.
- Conditions
- Non Small Cell Lung Cancer, Colorectal Cancer, Cervical Cancer, Locally Advanced or Metastatic Solid Tumors
- Trial name
- NCT07202364
- Testing
- YL202
- Where
- China
- Volunteers
- 100 people
- Sponsor
- MediLink Therapeutics (Suzhou) Co., Ltd.
Locally Advanced or Metastatic Breast Cancer
A Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of YL202 in Patients With BC
This study is a multicenter, open-label, phase 2 clinical study to evaluate the efficacy, safety and pharmacokinetics of YL202 in patients with locally advanced or metastatic breast cancer with TNBC, HR-positive…
- Trial name
- NCT06439771
- Testing
- YL202 should be intravenously infused
- Where
- China
- Volunteers
- 180 people
- Sponsor
- MediLink Therapeutics (Suzhou) Co., Ltd.
Advanced Solid Tumor
A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors
A Phase 1 First-in-Human study of YL217 in Patients with Advanced Solid Tumors
- Trial name
- NCT06859762
- Testing
- YL217, Bevacizumab, 5-FU with leucovorin
- Where
- 21 sites in United States, China
- Volunteers
- 630 people
- Sponsor
- MediLink Therapeutics (Suzhou) Co., Ltd.
Thoracic Neoplasms, Lung Diseases, Small Cell Lung Carcinoma
A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors
This is a phase Ib/II, multicenter, open-label study of YL201 combined with atezolizumab. The study will include 2 parts. Part 1 of the study is a dose escalation in participants with previously untreated ES-SCLC to determine the…
- Trial name
- NCT07407933
- Testing
- YL201, Atezolizumab
- Where
- 38 sites in United States, Belgium and 7 more
- Volunteers
- 118 people
- Sponsor
- MediLink Therapeutics (Suzhou) Co., Ltd.
Metastatic Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma (PDAC)
A Study to Compare the Efficacy and Safety of YL201 With Standard Chemotherapy in Patients With Metastatic Pancreatic Cancer After Failure of Gemcitabine-Based Systemic Chemotherapy
The purpose of this study is to evaluate the safety and efficacy of an investigational B7-H3 antibody drug-conjugate administered as monotherapy, compared with standard of care (SOC) chemotherapy in metastatic pancreatic cancer…
- Trial name
- NCT07803783
- Testing
- Tambotatug pelitecan, Liposomal irinotecan, 5 Fluorouracil
- Where
- China
- Volunteers
- 320 people
- Sponsor
- MediLink Therapeutics (Suzhou) Co., Ltd.
SCLC, Extensive Stage
A Study of YL201 in Combination With Serplulimab in Participants With Treatment-naïve Extensive-stage Small Cell Lung Cancer
This trial is a registrational Phase III, randomized, open-label, multicenter study to compare the efficacy and safety of YL201 in combination with serplulimab versus standard-of-care carboplatin and etoposide in combination with…
- Trial name
- NCT07739758
- Testing
- YL201, Serplulimab, Carboplatin
- Where
- 2 sites in China
- Volunteers
- 442 people
- Sponsor
- MediLink Therapeutics (Suzhou) Co., Ltd.
Advanced Solid Tumors
Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors
This is a multicenter, open-label, Phase 1 study. The study will enroll subjects with advanced solid tumors. It consists of six parts.
- Trial name
- NCT06384352
- Testing
- YL211, YL211+Pembrolizumab, YL211 + Pembro or Pembro+ Pemetrexed + (Carboplatin or Cisplatin)
- Where
- 21 sites in United States, Australia and 2 more
- Volunteers
- 500 people
- Sponsor
- MediLink Therapeutics (Suzhou) Co., Ltd.
Advanced Esophageal Squamous Cell Carcinoma
A Study of YL201 Versus Investigator's Choice of Chemotherapy in Participants With Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Failure of First-Line Therapy
This is a large clinical study carried out at multiple hospitals. Participants will be randomly assigned to one of two groups: one group will receive a new medicine called YL201, and the other group will receive standard…
- Trial name
- NCT07487896
- Testing
- YL201, Paclitaxel, Docetaxel
- Where
- 81 sites in China
- Volunteers
- 440 people
- Sponsor
- MediLink Therapeutics (Suzhou) Co., Ltd.
Advanced Solid Tumor
A Study of YL201 in Patients With Advanced Solid Tumors
This is a phase 1, multicenter, nonrandomized, open-label, first-in-human study of YL201 conducted in China and the United States.
- Trial name
- NCT05434234
- Testing
- YL201, YL201 and atezolizumab
- Where
- 45 sites in United States, Canada and 4 more
- Volunteers
- 312 people
- Sponsor
- MediLink Therapeutics (Suzhou) Co., Ltd.
Advanced Solid Tumors, Non Small Cell Lung Cancer
A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors
This study was designed to evaluate the efficacy and safety of YL201 in combination with Ivonescimab (AK112) in subjects with solid tumor.
- Conditions
- Advanced Solid Tumors, Non Small Cell Lung Cancer, Small Cell Lung Cancer
- Trial name
- NCT07208773
- Testing
- YL201, Ivonescimab
- Where
- China
- Volunteers
- 260 people
- Sponsor
- MediLink Therapeutics (Suzhou) Co., Ltd.